PRP-fibrinogen gel-like chondrocyte carrier stabilized by TXA-preliminary study.

Three dimensional scaffolds are becoming increasingly popular in the treatment of cartilage defects. Platelet-rich plasma (PRP) and fibrinogen can be used potentially as a three dimensional cell delivery vehicle. PRP is a fraction of plasma containing high levels of growth factors such as PDGF, IGF-I and TGF-I, which stimulate chondrocyte to synthesize extracellular matrix. The aim of this study was to prepare grafts based on fibrinogen, and PRP with fibrinogen as a chondrocyte carrier. Another goal was to estimate tranexamic acid as an antifibrynolytic agent in chondrocyte grafts and in monolayer culture for about 3 weeks. 450 ml blood was collected to produce fibrinogen and PRP from a Regional Blood Center voluntary donor. To prepare gel grafts, chondrocytes were mixed with PRP and, fibrinogen and then with thrombin in calcium chloride. Different doses of tranexamic acid or aprotinin were used to stabilize the constructs. Grafts were cultivated for 4 weeks in vitro to evaluate and compare their disintegration. Grafts were stable for the entire observation period and revealed no shrinkage. During graft storage, cells appeared to be viable, and cell migration from the graft to the culture plate was observed. Chondrocyte graft preparation based on PRP and fibrinogen is a promising method. PRP-fibrinogen carrier in combination with cells constitutes highly plastic and adhesive grafts. Tranexamic acid can be used as an anti-fibrinolytic agent in chondrocyte graft preparation instead of aprotinin.